JP2021052791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021052791A5 JP2021052791A5 JP2020211507A JP2020211507A JP2021052791A5 JP 2021052791 A5 JP2021052791 A5 JP 2021052791A5 JP 2020211507 A JP2020211507 A JP 2020211507A JP 2020211507 A JP2020211507 A JP 2020211507A JP 2021052791 A5 JP2021052791 A5 JP 2021052791A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- nucleic acid
- conjugate according
- linker
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 210000001163 endosome Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022137571A JP7536328B2 (ja) | 2016-06-20 | 2022-08-31 | 抗体－薬物コンジュゲート |
| JP2024124515A JP2024153831A (ja) | 2016-06-20 | 2024-07-31 | 抗体－薬物コンジュゲート |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016122187 | 2016-06-20 | ||
| JP2016122187 | 2016-06-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524078A Division JP6823269B2 (ja) | 2016-06-20 | 2017-06-19 | 抗体−薬物コンジュゲート |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137571A Division JP7536328B2 (ja) | 2016-06-20 | 2022-08-31 | 抗体－薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021052791A JP2021052791A (ja) | 2021-04-08 |
| JP2021052791A5 true JP2021052791A5 (enExample) | 2021-07-26 |
| JP7138965B2 JP7138965B2 (ja) | 2022-09-20 |
Family
ID=60784523
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524078A Active JP6823269B2 (ja) | 2016-06-20 | 2017-06-19 | 抗体−薬物コンジュゲート |
| JP2020211507A Active JP7138965B2 (ja) | 2016-06-20 | 2020-12-21 | 抗体－薬物コンジュゲート |
| JP2022137571A Active JP7536328B2 (ja) | 2016-06-20 | 2022-08-31 | 抗体－薬物コンジュゲート |
| JP2024124515A Pending JP2024153831A (ja) | 2016-06-20 | 2024-07-31 | 抗体－薬物コンジュゲート |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524078A Active JP6823269B2 (ja) | 2016-06-20 | 2017-06-19 | 抗体−薬物コンジュゲート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137571A Active JP7536328B2 (ja) | 2016-06-20 | 2022-08-31 | 抗体－薬物コンジュゲート |
| JP2024124515A Pending JP2024153831A (ja) | 2016-06-20 | 2024-07-31 | 抗体－薬物コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190240346A1 (enExample) |
| EP (2) | EP4212176A1 (enExample) |
| JP (4) | JP6823269B2 (enExample) |
| CN (1) | CN109310765A (enExample) |
| DK (1) | DK3473270T5 (enExample) |
| WO (1) | WO2017221883A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| CN109310765A (zh) * | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | 抗体-药物偶联物 |
| WO2018129384A1 (en) | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| SG11202003126VA (en) | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| CN118667812A (zh) | 2017-12-06 | 2024-09-20 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| KR20210086601A (ko) * | 2018-08-02 | 2021-07-08 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도 |
| US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EA202190417A1 (ru) * | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комплексы и их применение для лечения болезни помпе |
| EP3829594A4 (en) * | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| EP3829645A4 (en) * | 2018-08-02 | 2022-05-18 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020028844A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating centronuclear myopathy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028836A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| MX2021001283A (es) * | 2018-08-02 | 2021-07-15 | Dyne Therapeutics Inc | Complejos dirigidos al músculo y sus usos para tratar la distrofia miotónica. |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| CN112930197A (zh) * | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| JP7592034B2 (ja) | 2019-06-06 | 2024-11-29 | アビディティー バイオサイエンシーズ，インク． | 核酸ポリペプチド組成物およびその使用 |
| KR20220019259A (ko) | 2019-06-06 | 2022-02-16 | 어비디티 바이오사이언시스 인크. | Una 아미다이트 및 이의 용도 |
| WO2020247738A1 (en) * | 2019-06-07 | 2020-12-10 | Dyne Therapeutics, Inc. | Methods of preparing protein-oligonucleotide complexes |
| WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
| BR112022013686A2 (pt) * | 2020-01-10 | 2022-09-06 | Dyne Therapeutics Inc | Complexos de direcionamento a músculo e usos dos mesmos para tratar distrofia miotônica |
| US20230088865A1 (en) * | 2020-01-10 | 2023-03-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| CN115335062A (zh) * | 2020-01-10 | 2022-11-11 | 达因疗法公司 | 肌肉靶向复合物及其用于调节与肌肉健康相关的基因的用途 |
| WO2021154477A1 (en) * | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| MX2022009418A (es) * | 2020-01-31 | 2022-08-25 | Dyne Therapeutics Inc | Anticuerpo del receptor anti-transferrina (tfr) y usos del mismo. |
| EP4121063A4 (en) | 2020-03-19 | 2024-07-03 | Avidity Biosciences, Inc. | COMPOSITIONS AND METHODS FOR TREATING FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| JP7748962B2 (ja) | 2020-03-27 | 2025-10-03 | アビディティー バイオサイエンシーズ，インク． | 筋ジストロフィーを処置するための組成物および方法 |
| EP4185314A4 (en) * | 2020-07-23 | 2024-08-07 | Dyne Therapeutics, Inc. | MUSCLE-TARGETED COMPLEXES AND USES THEREOF FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2022147207A1 (en) * | 2020-12-31 | 2022-07-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| EP4317337A4 (en) | 2021-03-26 | 2024-08-14 | Fujimi Incorporated | Polishing method, method for producing semiconductor substrate, and polishing composition set |
| BR112023021318A2 (pt) * | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| EP4366784A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JPWO2023026994A1 (enExample) | 2021-08-21 | 2023-03-02 | ||
| US20240366775A1 (en) | 2021-08-24 | 2024-11-07 | Peptidream Inc. | Human transferrin receptor binding antibody-peptide conjugate |
| US11827702B2 (en) | 2021-09-01 | 2023-11-28 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
| KR20240055874A (ko) | 2021-09-16 | 2024-04-29 | 어비디티 바이오사이언시스 인크. | 안면견갑상완 근이영양증을 치료하는 조성물 및 방법 |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| WO2024187057A2 (en) | 2023-03-08 | 2024-09-12 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US12409230B2 (en) | 2023-06-30 | 2025-09-09 | Avidity Biosciences, Inc. | Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy |
| WO2025024334A1 (en) | 2023-07-21 | 2025-01-30 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| TW202517685A (zh) | 2023-10-26 | 2025-05-01 | 美商百健Ｍａ公司 | 抗運鐵蛋白受體抗體及其用途 |
| WO2025090121A1 (en) * | 2023-10-27 | 2025-05-01 | Yale University | Conjugate and methods of treatment |
| WO2025168041A1 (zh) * | 2024-02-08 | 2025-08-14 | 成都新泽利医药科技有限公司 | 治疗2型炎症性疾病的组合物和方法 |
| WO2025207959A1 (en) | 2024-03-27 | 2025-10-02 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8903022D0 (en) * | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
| GB8903021D0 (en) * | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| EP0592677B1 (en) | 1992-02-18 | 2001-11-07 | Otsuka Kagaku Kabushiki Kaisha | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2395660A1 (en) * | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US7572895B2 (en) * | 2004-06-07 | 2009-08-11 | Raven Biotechnologies, Inc. | Transferrin receptor antibodies |
| US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
| US8354102B2 (en) * | 2007-05-15 | 2013-01-15 | Hoffmann-La Roche Inc. | Antibodies directed to mGluR7 |
| US10550195B2 (en) * | 2014-07-11 | 2020-02-04 | The Regents Of The University Of California | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies |
| MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| CN109310765A (zh) * | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | 抗体-药物偶联物 |
-
2017
- 2017-06-19 CN CN201780038198.4A patent/CN109310765A/zh active Pending
- 2017-06-19 JP JP2018524078A patent/JP6823269B2/ja active Active
- 2017-06-19 WO PCT/JP2017/022509 patent/WO2017221883A1/ja not_active Ceased
- 2017-06-19 EP EP22210104.0A patent/EP4212176A1/en active Pending
- 2017-06-19 DK DK17815351.6T patent/DK3473270T5/da active
- 2017-06-19 EP EP17815351.6A patent/EP3473270B1/en active Active
- 2017-06-19 US US16/311,464 patent/US20190240346A1/en active Pending
-
2020
- 2020-12-21 JP JP2020211507A patent/JP7138965B2/ja active Active
-
2022
- 2022-08-31 JP JP2022137571A patent/JP7536328B2/ja active Active
-
2024
- 2024-04-16 US US18/637,050 patent/US20250082772A1/en active Pending
- 2024-07-31 JP JP2024124515A patent/JP2024153831A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021052791A5 (enExample) | ||
| Zuckerman et al. | Clinical experiences with systemically administered siRNA-based therapeutics in cancer | |
| JP2023103244A5 (enExample) | ||
| Chi et al. | Safety of antisense oligonucleotide and siRNA-based therapeutics | |
| Judge et al. | Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice | |
| Höbel et al. | Polyethylenimine/small interfering RNA‐mediated knockdown of vascular endothelial growth factor in vivo exerts anti‐tumor effects synergistically with Bevacizumab | |
| Kang et al. | Evaluation of folate‐PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo | |
| AU2013296321B2 (en) | Modified RNAi agents | |
| US11085044B2 (en) | miRNA for treatment of breast cancer | |
| JP2016506240A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| HRP20181030T1 (hr) | PRIPRAVCI iRNA SERPINA1 I POSTUPCI NJIHOVE UPORABE | |
| JP7023834B2 (ja) | 治療用オリゴヌクレオチド | |
| JP2023545502A (ja) | リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法 | |
| CN116887842A (zh) | 用于抑制angptl3的新型rna组合物和方法 | |
| CN115176011A (zh) | 用于抑制pcsk9的组合物和方法 | |
| US20160168573A1 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
| CN120591279A (zh) | 用于治疗癌症的方法和组合物 | |
| TW201250005A (en) | Microrna as a cancer progression predictor and its use for treating cancer | |
| KR20220110723A (ko) | 암 치료를 위한 TGF-β SIRNA 및 PDL1 SIRNA의 공동 전달 | |
| AU2021413862A1 (en) | Template directed immunomodulation for cancer therapy | |
| CA2530125A1 (en) | Use of double-stranded ribonucleic acid for inducing cell lysis | |
| US11149274B2 (en) | Methods and compositions for managing vascular conditions | |
| Yang et al. | Targeted TFO delivery to hepatic stellate cells | |
| US9320814B2 (en) | Polyplexes of hydrophobically-modified siRNA for delivery of siRNA |